Fuji Pharma Co., Ltd. AI Stock Analysis
Want to see JP:4554 full AI Analyst Report?
Fuji Pharma Co., Ltd. (4554) AI Stock Analysis
Fuji Pharma Co., Ltd.
(TSE/TYO:4554)
The overall score of 62 reflects a company with a solid financial foundation but facing operational headwinds. The primary strength is a significantly improved balance sheet and cash flow generation, which reduces financial risk. The main detractor is declining profitability and margins, which weigh on the financial performance score. Technicals are lackluster, with the stock in a longer-term downtrend, while the valuation is fair, offering some support.
Fuji Pharma Co., Ltd. (4554) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 46.15B
- Dividend Yield
- 2.27%
- Average Volume (3M)
- 125.33K
- Price to Earnings (P/E)
- 15.9
- Beta (1Y)
- 0.79
- Revenue Growth
- 20.72%
- EPS Growth
- -10.35%
- Country
- Japan
- Employees
- 1,760
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Fuji Pharma Co., Ltd. Business Overview & Revenue Model
Company Description
Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes...
Fuji Pharma Co., Ltd. Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is strong with improving leverage (debt-to-equity 0.41) and cash flow has turned robustly positive (FCF ¥4.1B TTM). However, profitability is declining, with net margin compressing to 4.5% TTM and ROE falling to 5.4%, which tempers the overall score.
Income Statement
58NeutralBalance Sheet
72PositiveCash Flow
65Positive| Breakdown | TTM | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.39B | 62.39B | 51.68B | 46.14B | 40.89B | 35.43B |
| Gross Profit | 24.32B | 22.77B | 19.29B | 16.51B | 15.37B | 13.62B |
| EBITDA | 9.47B | 6.36B | 8.96B | 7.56B | 6.88B | 6.52B |
| Net Income | 2.83B | 2.83B | 3.00B | 6.15B | 3.44B | 2.70B |
Balance Sheet | ||||||
| Total Assets | 98.29B | 98.29B | 93.63B | 90.58B | 86.40B | 75.97B |
| Cash, Cash Equivalents and Short-Term Investments | 9.50B | 9.50B | 7.25B | 4.58B | 2.32B | 3.55B |
| Total Debt | 28.37B | 28.37B | 30.94B | 29.25B | 28.95B | 24.57B |
| Total Liabilities | 45.83B | 45.83B | 46.72B | 45.01B | 45.22B | 40.17B |
| Stockholders Equity | 52.45B | 52.45B | 46.91B | 45.56B | 41.17B | 35.80B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 4.08B | 3.82B | 1.37B | -1.41B | -5.75B |
| Operating Cash Flow | 0 | 6.17B | 5.80B | 4.15B | 1.92B | -658.00M |
| Investing Cash Flow | 0 | -3.63B | -4.22B | -1.66B | -5.24B | -11.27B |
| Financing Cash Flow | 0 | -429.00M | 954.00M | -435.00M | 1.92B | 5.09B |
Fuji Pharma Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4554, the sentiment is Negative. The current price of 1770.00 is below the 20-day moving average (MA) of 1839.15, below the 50-day MA of 1805.29, and below the 200-day MA of 2023.54, indicating a bearish trend. The MACD of -0.79 indicates Positive momentum. The RSI at 43.14 is Neutral, neither overbought nor oversold. The STOCH value of 22.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4554.
Fuji Pharma Co., Ltd. Peers Comparison
Overall Rating
JP:453473Outperform
JP:488669Neutral
JP:457767Neutral
JP:453863Neutral
JP:455462Neutral
JP:456958Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | JPY 114.51B | 11.14 | 7.68% | 2.45% | 15.85% | 60.55% | |
| 69Neutral | JPY 56.74B | 11.43 | ― | 3.05% | ― | 9.04% | |
| 67Neutral | JPY 37.71B | 11.98 | ― | 3.06% | -2.83% | 65.69% | |
| 63Neutral | JPY 19.04B | 8.28 | ― | 4.15% | 2.29% | ― | |
| 62Neutral | JPY 46.15B | 15.93 | 5.56% | 2.27% | 20.72% | -10.35% | |
| 58Neutral | JPY 57.90B | 161.98 | ― | 4.27% | -6.48% | -95.83% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4554 | Fuji Pharma Co., Ltd. | 1770.00 | 52.22 | 3.04% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3365.00 | 84.75 | 2.58% | |
| JP:4538 | Fuso Pharmaceutical Industries,Ltd. | 2170.00 | 60.42 | 2.86% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1100.00 | -335.63 | -23.38% | |
| JP:4577 | Daito Pharmaceutical Co., Ltd. | 1307.00 | 77.98 | 6.34% | |
| JP:4886 | ASKA Pharmaceutical Holdings Co., Ltd. | 2132.00 | 127.40 | 6.36% |
Fuji Pharma Co., Ltd. Corporate Events
Fuji Pharma Raises Year-End Dividend to 29 Yen Per Share
Fuji Pharma’s board resolved on November 10, 2026, to pay a year-end dividend of 29 yen per share for a September 30, 2026 record date, totaling 758 million yen from retained earnings. The dividend’s effective date is December 21, 2026.Fuji Pharma sa...
Fuji Pharma Reports Fiscal 2026 Consolidated Results
Fuji Pharma Co., Ltd., listed on the Tokyo Stock Exchange under code 4554, released consolidated financial results for the fiscal year ended September 30, 2026. The release reports results under Japanese GAAP for the period from October 1, 2025, thro...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
